New Drug Blocks Pain Signals at Source in Trial, Journal Reports

The trial, shared by the journal on X, focuses on a class of compound that targets Nav1.8, a sodium channel (a tiny protein gateway in nerve cells that allows electrical signals to pass through) thought to play a direct role in how the body transmits sharp, short-term pain. By blocking this channel, researchers are testing whether the drug can reduce acute pain without the broader side effects associated with existing painkillers.

The New England Journal of Medicine, one of the world’s longest-running peer-reviewed medical publications, posted the study under the tags neurology and surgery — suggesting the research has potential relevance for post-operative pain management as well as other acute pain settings.

Phase 2b is a mid-stage trial. It sits after early safety testing but before the larger phase 3 studies needed to seek regulatory approval. Results at this stage can indicate whether a drug is working well enough to justify that next, more expensive step.

The trial does not yet have impact on NHS prescribing. Any new drug would need to complete phase 3 trials and pass assessment by the Medicines and Healthcare products Regulatory Agency (MHRA) before it could be considered for use in UK hospitals or GP surgeries.

Residents with concerns about pain management should speak to their GP in the first instance, or contact NHS 111 for non-emergency advice.